BIO Announces 2002-2003 Board of Directors
Toronto (June 12, 2002) - The Biotechnology Industry Organization (BIO) has named its 2002-2003 Board of Directors, which includes nine new members: Goran Ando, M.D., executive vice president/president for research and development of Pharmacia Corporation; Andrew Baum, president and CEO of SemBioSys Genetics, Inc.; Joshua Boger, Ph.D., chairman and CEO of Vertex Pharmaceuticals, Inc.; Bruce L.A. Carter, Ph.D., president and CEO of ZymoGenetics, Inc.; Russell Howard, Ph.D., CEO of Maxygen; Richard DiMarchi, Ph.D., group vice president of Eli Lilly and Company; W. Scott Harkonen, M.D., president and CEO of InterMune, Inc.; Mitchel Sayare, chairman and CEO of ImmunoGen Inc.; and Leonard Schleifer, M.D., Ph.D., president and CEO of Regeneron Pharmaceuticals, Inc. David E. Robinson will continue as chairman of the board. Robinson is chairman, president and CEO of Ligand Pharmaceuticals, Inc.
"Our board includes leaders of companies at every stage of development, from startups to large-cap multinationals," said BIO President Carl B. Feldbaum. "That breadth of experience among BIO's stewards will serve our membership well over the coming year as we deal with multiple challenges: Medicare reform and efforts to design a prescription drug benefit, implementation of the Prescription Drug User Fee Act, acceptance of agricultural biotechnology, acceleration of biodefense research, tax and accounting proposals, and a range of international trade and patent issues."
Board of Directors
| * Goran Ando, M.D. Executive Vice President/ President for R&D Pharmacia Corporation Peapack, NJ | Benjamin F. McGraw, Ph.D. Chairman, President & CEO Valentis, Inc. Burlingame, CA |
| David W. Anstice President, Human Health- The Americas Merck & Co., Inc. North Wales, PA | Alex McPherson, M.D., Ph.D. President & CEO Biomira, Inc. Edmonton, Alberta, Canada |
| *Andrew Baum President & CEO SemBioSys Genetics, Inc. Calgary, Alberta, Canada | Howard L. Minigh Group Vice President DuPont Biosolutions Enterprise Wilmington, DE |
| Ernesto Bertarelli Chief Executive Officer Serono International SA Geneva, Switzerland | Walter H. Moos, Ph.D. Chairman and CEO Mitokor San Diego, CA |
| Simon G. Best Chief Executive Officer Ardana Bioscience LTD Edinburgh, United Kingdom | James C. Mullen President & CEO Biogen, Inc. Cambridge, MA |
| * Joshua Boger, Ph.D. Chairman & CEO Vertex Pharmaceuticals, Inc. Cambridge, MA | H. Stewart Parker President & CEO Targeted Genetics Corporation Seattle, WA |
| * Bruce L.A. Carter, Ph.D. President & CEO ZymoGenetics, Inc. Seattle, WA | Richard F. Pops Chief Executive Officer Alkermes, Inc. Cambridge, MA |
| Nancy T. Chang, Ph.D. President & CEO Tanox, Inc. Houston, TX | Edwin C. Quattlebaum, Ph.D. Chairman, President & CEO MetaMorphix, Inc. Savage, MD |
| Robert Chess Chairman Inhale Therapeutic Systems, Inc. San Carlos, CA | Hollings C. Renton Chairman and CEO Onyx Pharmaceuticals, Inc. Richmond, CA |
| * Richard D. DiMarchi, Ph.D. Group Vice President Eli Lilly and Company Indianapolis, IN | Norbert G. Riedel, Ph.D. Corporate Vice President & Chief Scientific Officer Baxter International, Inc. Roundlake, IL |
| Douglas A. Doerfler President and CEO MaxCyte, Inc. Rockville, MD | David E. Robinson Chairman, President & CEO Ligand Pharmaceuticals, Inc. San Diego, CA |
| Dennis M. Fenton, Ph.D. Executive Vice President Amgen Thousand Oaks, CA | Duane J. Roth Chairman & CEO Alliance Pharmaceutical Corp. San Diego, CA |
| A. Charles Fischer President & CEO Dow AgroSciences Indianapolis, IN | Una S. Ryan, Ph.D. President & CEO AVANT Immunotherapeutics, Inc. Needham, MA |
| Edward V. Fritzky Chairman, CEO, and President Immunex Corporation Seattle, WA | * Mitchel Sayare, Ph.D. Chairman & CEO ImmunoGen, Inc. Cambridge, MA |
| L. Patrick Gage, Ph.D. President Wyeth Research Collegeville, PA | * Leonard S. Schleifer, M.D., Ph.D. President & CEO Regeneron Pharmaceuticals, Inc. Tarrytown, NY |
| Donal Geaney Chairman and CEO Elan Corporation, plc Dublin, Ireland | Stephen A. Sherwin, M.S. Chairman & CEO Cell Genesys, Inc. Foster City, CA |
| * W. Scott Harkonen, M.D. President and CEO InterMune, Inc. Brisbane, CA | Edward T. Shonsey President & CEO Syngenta Seeds, Inc. Golden Valley, MN |
| William A. Haseltine, Ph.D. Chairman and CEO Human Genome Sciences, Inc. Rockville, MD | Mark Skaletsky Chairman & CEO Essential Therapeutics Waltham, MA |
| Susan Desmond Hellmann, M.D., M.P.H. Executive Vice President, Development & Product Operations and Chief Medical Officer Genentech, Inc. South San Francisco, CA | Frederick W. Telling, Ph.D. Vice President, Corporate Policy & Strategic Management Pfizer, Inc. New York, NY |
| Wayne T. Hockmeyer, Ph.D. Chairman MedImmune, Inc. Gaithersburg, MD | Henri A. Termeer Chairman and CEO Genzyme Corporation Cambridge, MA |
| * Russell J. Howard, Ph.D. Chief Executive Officer Maxygen, Inc. Redwood City, CA | Hendrik Verfaillie President & CEO Monsanto Company St. Louis, MO |
| Vaughn M. Kailian Vice Chairman Millennium Pharmaceuticals, Inc. Cambridge, MA | Roy A. Whitfield Chairman of the Board of Directors Incyte Genomics, Inc. Palo Alto, CA |
| Louis G. Lange, M.D., Ph.D. Chairman and CEO CV Therapeutics, Inc. Palo Alto, CA | Thomas G. Wiggans President & CEO Connetics Corporation Palo Alto, CA |
| Edward Lanphier President & CEO Sangamo BioSciences, Inc. Richmond, CA |
* New Board Member
###